Well said. I agree, there's something very odd about this company. A really promising molecule with everything going for it, such poor management, funds sought from odd places like Morocco, a BP offer turned down, no progress on BOM2 or the covid trial. It's almost as if somebody wants to keep the share price at rock bottom.